Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non–Small-Cell Lung Cancer: Final Results From SWOG S1403

PURPOSE: The irreversible ErbB family tyrosine kinase inhibitor (TKI) afatinib plus the EGFR monoclonal antibody cetuximab was previously shown to overcome resistance to EGFR TKIs. We studied whether the combination of afatinib plus cetuximab compared with afatinib alone would improve progression-fr...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Clin Oncol
Huvudupphovsmän: Goldberg, Sarah B., Redman, Mary W., Lilenbaum, Rogerio, Politi, Katerina, Stinchcombe, Thomas E., Horn, Leora, Chen, Everett H., Mashru, Sandeep H., Gettinger, Scott N., Melnick, Mary Ann, Herbst, Roy S., Baumgart, Megan A., Miao, Jieling, Moon, James, Kelly, Karen, Gandara, David R.
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Society of Clinical Oncology 2020
Ämnen:
ORIGINAL REPORTS
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7768342/
https://ncbi.nlm.nih.gov/pubmed/33021871
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.01149
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk